Mesoblast Chief Medical Officer Dr Fred Grossman said: “The extensive body of safety and efficacy data generated to date using remestemcel-L in children with graft versus host disease suggest that our cellular therapy could provide a clinically important therapeutic benefit in MIS-C patients, especially if the heart is involved as a target organ for inflammation. Use of remestemcel-L in children with COVID-19 builds on and extends the potential application of this cell therapy in COVID-19 cytokine storm beyond the most severe adults with acute respiratory distress syndrome.”
So exciting!
Ann: EAP for Remestemcel-L in Children with MIS-C due to COVID-19, page-3
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
-0.063(4.27%) |
Mkt cap ! $1.581B | |||
| Open | High | Low | Value | Volume |
| $1.45 | $1.46 | $1.37 | $5.315M | 3.784M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 25850 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.41 | 15708 | 14 |
View Market Depth
| Last trade - 13.04pm 09/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |